About Indus Pharma Private Limited
Data last updated:
Indus Pharma Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 12 January 1987 and has been in existence for over 39 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74899DL1987PTC026657. Its GSTIN is 08AAACI1456P1Z9 (Rajasthan).
The company has an authorised share capital of ₹70 Lakh and a paid-up capital of ₹20 Lakh. It is led by directors including Radhey Shyam Arora (Managing Director) and Surinder Arora.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 5/2 Industrial Area Kirti Nagar, New Delhi, Delhi, India – 110015.
As per the financials filed for FY 2023, the company reported a revenue of ₹28.11 Cr, a decline of 58% compared to the previous year. For the same year it recorded a net profit of ₹1.66 Cr (net margin 5.9%) and EBITDA of ₹4.53 Cr (EBITDA margin 16.1%). Revenue has declined at a compounded annual rate (CAGR) of 8% over three years.
The company has about 46 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Indus Pharma. As per MCA filings, the company has open charges of ₹12 Cr and satisfied charges of ₹20.57 Cr on record. Court records list 9 cases involving the company, including 8 filed by the company; 2 cases are pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website induspharmaindia.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address5/2 Industrial Area Kirti Nagar, New Delhi, Delhi, India – 110015
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Indus Pharma Private Limited
The main business activities of Indus Pharma are manufacturing and trade. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and wholesale trading. 2 activity segments are registered with the MCA.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Indus Pharma Private Limited FY 2024 filings available
Indus Pharma Private Limited reported revenue of ₹28.11 Cr (down 58% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR) of Indus Pharma Private Limited
Revenue has declined at a compounded annual rate (CAGR) of 8% over three years, including a 58% fall in the latest year. EBITDA fell 69% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Indus Pharma Private Limited
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹4.53 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹1.66 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Indus Pharma Private Limited
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 16.1% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 5.9% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Indus Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Indus Pharma Private Limited
Indus Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Alicon Pharmaceutical Private Limited | ₹28.34 Cr (FY 2024) | •••• | •••• | 28.0% | •••• | Palghar, Maharashtra, India |
| Eisen Pharmaceutical Company (Private) Limited | ₹28.28 Cr (FY 2025) | •••• | •••• | 16.0% | •••• | Pune, Maharashtra, India |
| Astra-Idl Limited | ₹28.28 Cr (FY 2024) | •••• | •••• | 120.0% | •••• | Mumbai, Maharashtra, India |
| Kamlaamrut Pharmaceutical LLP | ₹28.26 Cr (FY 2023) | •••• | •••• | 34.0% | •••• | Kalol, Gujarat, India |
| Medicaps Limited Listed | ₹28.21 Cr (FY 2025) | •••• | •••• | 1.0% | •••• | Indore, Madhya Pradesh, India |
| Indus Pharma Private Limited this company | ₹28.11 Cr (FY 2023) | •••• | •••• | -58.0% | •••• | New Delhi, Delhi, India |
| Novita Healthcare Private Limited | ₹28.02 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Mumbai, Maharashtra, India |
| Inven Pharmaceuticals Private Limited | ₹27.99 Cr (FY 2025) | •••• | •••• | -6.0% | •••• | Indore, Madhya Pradesh, India |
| Aashka Formulation Private Limited | ₹27.95 Cr (FY 2022) | •••• | •••• | 904.0% | •••• | Kalol, Gujarat, India |
| Danashmand Organic Private Limited | ₹27.92 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Mumbai, Maharashtra, India |
| Shreepati Pharmaceuticals Pvt Ltd | ₹27.91 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Indore, M.P, Madhya Pradesh, India |
Peers are the five companies nearest above and the five nearest below Indus Pharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Indus Pharma Private Limited
Indus Pharma Private Limited is audited by ARORA GUPTA AND GOEL for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| ARORA GUPTA AND GOEL | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Indus Pharma Private Limited
Indus Pharma has 3 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Radhey Shyam Arora Also directs: Indus Versatile Private Limited | Managing Director | 12 Jan 1987 | 39 Years 8 Months | Current |
| Surinder Arora | Director | 15 Jun 2016 | 10 Years 3 Months | Current |
| Mukta Arora Also directs: Indus Versatile Private Limited | Director | 15 Jun 2016 | 10 Years 3 Months | Current |
Ownership and Shareholding of Indus Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Indus Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Sep 2020 | Others | ₹6 Cr | Open |
| 21 Sep 2020 | Others | ₹6 Cr | Open |
| 26 Sep 2018 | Others | ₹4.25 Cr | Satisfied |
| 12 Jan 2017 | Sidbi | ₹3.25 Cr | Satisfied |
| 12 Jan 2017 | Sidbi | ₹7.7 Cr | Satisfied |
Total charge records: 13 View all charges
Legal Cases of Indus Pharma Private Limited
Indus Pharma Private Limited has 9 court cases on record: 8 filed by Indus Pharma, 1 where it is another party. 2 cases are pending and 7 are disposed. Status as checked between 21 Sep 2026 and 03 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 8 | 0 | 2 |
| District courts | 1 | 0 | 0 |
Cases on record (5 of 9)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Rajasthan | Interim or miscellaneous application | Filed by the company against State of Rajasthan | Pending |
| High Court of Rajasthan | Writ petition | Filed by the company against State of Rajasthan | Pending |
| High Court of Delhi | Writ petition | Filed by the company against Commissioner of Trade and Taxes & Anr | Disposed |
| High Court of Delhi | Writ petition | Filed by the company against Commissioner Trade and Taxes & Anr | Disposed |
| High Court of Delhi | Writ petition | Filed by the company against Commissioner, Trade and Taxes & Anr | Disposed |
Full case history
All 9 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Indus Pharma Private Limited
Indus Pharma Private Limited has 2 MSME Form 1 returns on record between 2018 and 2019, listing 7 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 7)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Harmony Pharma Glass Company | •••• | •••• | •••• |
| HBR Packaging | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Yacca Pharmaceuticals Private Limited | •••• | •••• | •••• |
| Tejas India Buildtech Private Limited | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 2 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Indus Pharma Private Limited
Indus Pharma operates one associated brand: Indus Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Indus Pharma is engaged in developing innovative pharmaceutical solutions. | induspharmaindia.com |
Employees and EPFO Compliance at Indus Pharma Private Limited
Indus Pharma Private Limited has a workforce of 46 employees as of Apr 08, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Indus Pharma Private Limited
Indus Pharma Private Limited has 4 board changes on record since 1987: 3 appointments and 1 cessation. The latest: Mukta Arora was appointed as Director on 15 Jun 2016.
24 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Indus Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Indus Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Indus Pharma Private Limited
Indus Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 08AAACI1456P1Z9 | Rajasthan | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Indus Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Indus Pharma Private Limited
Indus Pharma is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 12 January 1987 (39+ years old) and is registered under CIN U74899DL1987PTC026657.
Indus Pharma reported revenue of ₹28.11 Cr for FY 2023 (down 58% YoY).
Indus Pharma has 3 current directors:
- Radhey Shyam Arora - Managing Director
- Surinder Arora - Director
- Mukta Arora - Director
Indus Pharma reported a net profit of ₹1.66 Cr (net margin 5.9%) and EBITDA of ₹4.53 Cr (EBITDA margin 16.1%) for FY 2023, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Indus Pharma is -8% over three years. In the latest year (FY 2023) revenue fell 58%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Indus Pharma is 08AAACI1456P1Z9, registered in Rajasthan.
The CIN (Corporate Identification Number) of Indus Pharma is U74899DL1987PTC026657. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Indus Pharma has 9 court cases on record: 8 filed by the company. 2 are pending. Most are in the high courts.
Indus Pharma was incorporated on 12 January 1987, making it 39+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Indus Pharma by revenue are Alicon Pharmaceutical Private Limited, Eisen Pharmaceutical Company (Private) Limited, Astra-Idl Limited, Kamlaamrut Pharmaceutical LLP, Medicaps Limited and 5 more, all in the Pharma industry (Formulations).
Mukta Arora was appointed as Director on 15 Jun 2016. Surinder Arora was appointed as Director on 15 Jun 2016. Surinder Kumar ceased to be Director on 15 Jun 2016. Indus Pharma has 4 board changes on record in total.
Indus Pharma has 2 MSME Form 1 returns on record between 2018 and 2019, listing 7 overdue payments to 7 micro and small suppliers. The latest return was filed on 28 May 2019.